The anti-obesity drugs rimonabant and taranabant are inverse agonists at the cannabinoid CB1 receptor and though they produced significant weight loss, both were withdrawn owing to a high incidence of depression and anxiety, which are believed to relate to the inhibition of the constitutive activity of the cannabinoid receptor.
Obat anti-obesitas rimonabant dan taranabant adalah agonis terbalik pada reseptor cannabinoid CB1 dan meskipun mereka menghasilkan penurunan berat badan yang signifikan, keduanya ditarik karena tingginya insiden depresi dan kecemasan, yang diyakini berkaitan dengan penghambatan aktivitas konstitutif reseptor cannabinoid.